Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …

Importance Patients with locally advanced pancreatic cancer have historically poor
outcomes. Evaluation of a total neoadjuvant approach is warranted. Objective To evaluate …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

Importance Patients with borderline-resectable pancreatic ductal adenocarcinoma have
historically poor outcomes with surgery followed by adjuvant chemotherapy. Evaluation of a …

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …

Radiation therapy (RT) continues to play an important role in the treatment of cancer.
Adaptive RT (ART) is a novel method through which RT treatments are evolving. With the …

Background Adaptive magnetic resonance imaging‐guided radiation therapy (MRgRT) can
escalate dose to tumors while minimizing dose to normal tissue. We evaluated outcomes of …